Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON31070Phase 3Recruiting
Phase 3, open-label trial of remifentanil (2 arms), sponsored by OLVG West. Primary endpoint: Patients' satisfaction. Started Mar 2008; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON31070.